Você procurou por: jissuġerixxu (Maltês - Inglês)

jekk tħoss sintomi li jistgħu jissuġerixxu ħsara lill- fwied, bħal
if you experience symptoms suggesting a damage of the liver, such as

ir-rapporti jissuġerixxu li ceprotin hu ttollerat sew fi tfal u trabi żgħar.
the reports suggest that ceprotin is well tolerated in children and small infants.

riżultati tat-testijiet tad-demm jissuġerixxu indeboliment tal-fwied u l-kliewi
results of blood tests suggesting impaired liver and kidney function

studji eżawrjenti marbuta jissuġerixxu li riċevitur fil-membrana għal imiquimod jeżisti fiċ-ċelloli immuni li jirrispodu.
saturable binding studies suggest a membrane receptor for imiquimod exists on responding immune cells.

il-pazjenti għandhom jingħataw struzzjonijiet biex jirraportaw is-sinjali u s-sintomi kollha li jissuġerixxu infezzjoni.
patients must be instructed to report all signs and symptoms suggestive of infection.

f’każ ta’ xi sintomi li jissuġerixxu reazzjonijiet ta’ sensittività eċċessiva, ikkuntatja lit- tabib tiegħek immedjatament
in case of any symptoms suggesting hypersensitivity reactions, contact your doctor immediately

jekk tħoss sintomi li jistgħu jissuġerixxu ħsara lill-fwied, bħal għandek tieqaf tieħu viramune u għandek tikkuntattja lit-tabib tiegħek minnufih.
if you experience symptoms suggesting damage of the liver, such as you should discontinue taking viramune and must contact your doctor immediately.

dawn l-istudji jissuġerixxu li l-potenzjal karċinoġeniku ta’ ribavirin fil- bniedem x’aktarx ma jseħħx.
these studies suggest that a carcinogenic potential of ribavirin in humans is unlikely.

sonovue m’għandux jintuża flimkien ma’ dobutamine f’pazjenti b’kundizzjonijiet li jissuġerixxu instabilità kardjovaskolari meta dobutamine jkun kontraindikat.
sonovue should not be used in combination with dobutamine in patients with conditions suggesting cardiovascular instability where dobutamine is contraindicated.

riżultati farmakokinetiċi jissuġerixxu li kawtela għandha tiġi eżerċitata meta nevirapine jingħata lil pazjenti li għandhom problemi moderati tal-fwied (child- pugh b).
pharmacokinetic results suggest caution should be exercised when nevirapine is administered to patients with moderate hepatic dysfunction (child-pugh b).

riżultati farmakokinetiċi jissuġerixxu li wieħed għandu joqgħod attent meta nevirapine jingħata lil pazjenti li għandhom problemi moderati tal-fwied (child-pugh b).
pharmacokinetic results suggest caution should be exercised when nevirapine is administered to patients with moderate hepatic dysfunction (child-pugh b).

sintomi li jissuġerixxu sindromu newrolettiku mallinn kienu rapportati mat- twaqqif f’ daqqa tat- terapija dopaminerġika (ara sezzjoni 4. 2).
symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see section 4.2.)